The GLP-1 Compounding Cliff Explained: What Changed in 2025–2026 and What Operators Do Now

Direct answer: Compounded GLP-1s (semaglutide and tirzepatide) are no longer broadly legal as of mid-2025. The FDA declared both drugs no longer in shortage — semaglutide in February 2025, tirzepatide in December 2024 — triggering wind-down deadlines for 503A and 503B compounders. What limited legal avenues remain are narrow and pharmacy-specific.

If you built your telehealth business around compounded semaglutide or tirzepatide, the ground moved under you fast. This post reconstructs the actual timeline, explains what the rules mean in plain language, and — more usefully — tells you what operators who built durable clinics are doing instead.

---

What Actually Happened, and When: The Real Timeline

Regulatory change is rarely clean. The GLP-1 situation was messier than most summaries suggest. Here is the sequence as it actually unfolded.

December 2024: Tirzepatide shortage resolved

The FDA removed tirzepatide (Mounjaro/Zepbound) from its drug shortage database in December 2024. Under the Federal Food, Drug, and Cosmetic Act, 503A pharmacies — the traditional compounding pharmacies that fill individual prescriptions — may only compound drugs that appear on the shortage list. Once tirzepatide came off it, 503A compounders lost their legal basis for producing it at scale.

The FDA gave 503A pharmacies a wind-down period. That window has now closed.

February 2025: Semaglutide shortage resolved

The FDA declared semaglutide (Ozempic/Wegovy) no longer in shortage in February 2025. The same logic applied. 503A compounders had a short runway — roughly 60 days — before compounding semaglutide for patient populations (rather than individual patient-specific needs) became legally untenable.

This was the moment most clinics felt the cliff in real time. Q1 2025 saw a flood of operator questions about what comes next.

April 2026: FDA removes GLP-1s from the 503B bulks list

This is the move that closed the last broad door. In April 2026, the FDA finalized its exclusion of semaglutide and tirzepatide from the list of bulk drug substances that 503B outsourcing facilities may use. 503B facilities had been operating under temporary enforcement discretion after the shortage resolutions — this action ended that discretion formally.

After April 30, 2026, a 503B outsourcing facility compounding semaglutide or tirzepatide from bulk API for non-shortage patients is not operating within FDA's framework. Full stop.

---

What Is Still (Narrowly) Legal?

Not everything is off the table. But the remaining pathways are genuinely narrow, and any operator treating them as business-as-usual is taking on meaningful legal and reputational risk. Here is an honest accounting.

Patient-specific compounding (503A) for documented allergies or clinical need. A 503A pharmacy may still compound a GLP-1 formulation for an individual patient who has a documented clinical need that a commercially available product cannot meet — a specific inactive-ingredient allergy, for instance. This must be a genuine patient-specific reason, not a category workaround. Volume matters: if your pharmacy is compounding this for thousands of patients simultaneously, that is not patient-specific compounding in the legal sense.

Commercially available products remain legal and fully covered by standard fulfillment. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are on-market branded products. Telehealth operators can build GLP-1 programs entirely around these — the fulfillment complexity is different (prior auth, insurance, assistance programs), but there is nothing legally ambiguous about prescribing commercially available Rx.

Always verify with your pharmacy and counsel. Compounding law is state-specific in addition to federal. Consult your compounding pharmacy, your pharmacy law counsel, and your state board of pharmacy before making any compounding-related claims to patients or adjusting your clinical workflows. This post is educational, not legal advice.

---

Why the GLP-1 Cliff Is Actually a Diagnostic

Here is the uncomfortable truth for any operator who is deep in this: the cliff exposed a structural fragility that was always there.

Clinics that built their entire revenue model on one compounded molecule — with pricing, margins, and patient acquisition all tuned to that molecule — were never really running a telehealth business. They were running a drug arbitrage business. The FDA can (and did) end that arbitrage with a single regulatory determination.

The operators who are coming out of 2025–2026 in the best shape have a few things in common:

• Multi-category formularies — TRT/men's health, HRT/menopause, hair loss, ED, tretinoin and skin, low-dose naltrexone (LDN), peptides, and oral weight-loss alternatives gave them revenue stability when the GLP-1 rules tightened.
• Owned patient relationships — they were the system of record for their patients, not a front end for a compounding pharmacy's patient list.
• Infrastructure that routes, not locks — when one pharmacy could no longer fill a script, they had the ability to route to another. They were not single-threaded to one compounding partner.

The category breadth is a compliance strategy, not just a growth strategy.

---

The 503A vs. 503B Distinction Matters More Than You Think

Most operators know the terms "503A" and "503B" but are fuzzy on the practical difference. That fuzziness cost some clinics real money in 2025. [See our detailed 503A vs. 503B breakdown →]

503A pharmacies compound for individual patients based on a valid prescription. They are regulated primarily at the state level, with federal oversight layered on top. They can only compound drugs in shortage (for population-level volume) or with a patient-specific clinical rationale. They cannot sell to other states without specific reciprocal arrangements, and they cannot compound in anticipation of prescriptions.

503B outsourcing facilities are federally registered, can compound without a patient-specific prescription, and can sell across state lines to hospitals, clinics, and other healthcare facilities. They operate under stricter federal cGMP standards. They had broader latitude on GLP-1s after the shortage resolutions — right up until April 2026, when that latitude was formally removed.

If your pharmacy relationship is with a 503B facility, the April 2026 FDA action is the primary constraint. If it is with a 503A pharmacy, the shortage resolutions in late 2024 and early 2025 were the trigger. The practical implication is the same either way: bulk compounded GLP-1 programs are no longer within the regulatory framework.

---

What Operators Are Doing Instead

The strongest clinics we have spoken to are doing a combination of the following. None of these require waiting for regulatory clarity. All of them work right now.

1. Branded product programs with real infrastructure. Prior auth workflows, manufacturer patient assistance programs (Lilly's program for Zepbound is aggressive on access), and GoodRx-type cash pricing pathways. The margin structure is different from compounding, but the patient can still get to medication.

2. Oral weight-loss alternatives. Metformin, topiramate, bupropion/naltrexone combinations — these are commercially available, well-studied, and sit entirely outside the compounding question. Some patients are better served by these anyway.

3. Category pivot to TRT, HRT, and skin. The compounding rules for testosterone (men's health) and certain hormone formulations (HRT, thyroid) are entirely different. Many of these are on the official shortage list or have established clinical compounding pathways. The patient acquisition mechanics are similar to GLP-1 telehealth; the regulatory posture is more stable.

4. LDN (low-dose naltrexone) programs. Naltrexone at standard doses is a commercially available generic. Low-dose naltrexone (1.5–4.5 mg) has no commercially available formulation, which means it genuinely qualifies for 503A patient-specific compounding. LDN programs for autoimmune conditions, fibromyalgia, and other indications have a defensible compounding path. [See our category diversification guide →]

5. Infrastructure that does not depend on any single molecule. This is the real answer. If your fulfillment layer is Shopify-native, routes to multiple pharmacies, and gives you the system of record for your patients, then any future regulatory shift — GLP-1 or otherwise — is a product decision, not an existential crisis.

---

The Deeper Compliance Framework: What Regulators Actually Care About

GLP-1 compounding dominated headlines, but operators should understand the underlying concerns driving FDA action. That understanding makes future regulatory moves more predictable.

The shortage exception is not a loophole. The compounding framework is designed to give patients access to medications when commercial supply cannot meet demand. It is not designed to create a parallel generic market for commercially available, brand-name products. When the FDA sees high-volume compounding of a drug that is readily available in its branded form, it moves toward shortage resolution — which is exactly what happened here.

503A volume is a red flag. If a 503A pharmacy is compounding the same drug for thousands of patients, that looks less like patient-specific compounding and more like manufacturing. FDA enforcement discretion on GLP-1s ended because the volume was staggering — estimates suggest hundreds of millions of dollars of compounded semaglutide was dispensed at peak. That scale invites scrutiny.

Provider approval is always required. Nothing in the GLP-1 situation changes the foundational rule: a licensed provider must review and approve every prescription before anything ships. That rule exists independently of which molecule is being dispensed. Operators who cut corners on provider review were exposed before the compounding cliff and remain exposed after it. [Learn how neolife structures the provider-in-the-loop →]

LegitScript certification matters even more now. If you are operating a DTC Rx telehealth site, LegitScript certification is not optional infrastructure — it is a marker of legitimacy that payment processors, advertising platforms, and pharmacy partners use to evaluate whether they want to work with you. The GLP-1 enforcement environment has pushed all major platforms to scrutinize telehealth advertisers more closely. Get certified before you spend meaningfully on paid acquisition. [How to approach LegitScript from Day 0 →]

---

What Does This Mean for My Clinic Specifically?

A few diagnostic questions to run on your own operation.

Are you still describing your product as "compounded semaglutide" or "compounded tirzepatide" in marketing materials or on your website? If so, stop. Update the copy. The liability exposure of marketing a compounded GLP-1 as a current, broadly available product is not worth it.

Does your pharmacy partner have a clear, written position on their current compounding authority for GLP-1s? If they cannot produce that in writing, including the legal basis under which they are operating, escalate. Pharmacy law counsel should be involved.

Do you own your patient data, or does your fulfillment platform hold it? If the pharmacy or a telehealth platform is the system of record for your patients, a regulatory shift or a contract dispute can separate you from your entire patient relationship history overnight. That is a structural risk that sits next to — and outlasts — the GLP-1 question.

What percentage of your revenue comes from GLP-1 adjacent SKUs? If it is above 50%, you need a category roadmap for 2026–2027 regardless of your current legal posture.

---

Key Takeaways

• Tirzepatide compounding ended broadly in December 2024 when the FDA removed it from the shortage list. 503A wind-down deadlines have passed.
• Semaglutide compounding ended broadly in February 2025 on the same basis.
• 503B outsourcing facilities lost their last GLP-1 pathway in April 2026 when the FDA excluded semaglutide and tirzepatide from the 503B bulks list.
• Narrow patient-specific compounding still exists for documented individual clinical needs, but is not a volume play.
• Branded GLP-1 products remain fully prescribable — the regulation is about compounding, not prescribing.
• Durable clinics diversified categories before the cliff arrived: TRT, HRT, LDN, skin, hair, ED, oral weight management.
• Provider approval is non-negotiable regardless of molecule. Every prescription, every time.
• Own your patient data and your system of record. A regulatory change should be a product decision, not a shutdown event.

---

FAQ

Q: Can I still prescribe semaglutide or tirzepatide at my telehealth clinic?

A: Yes. You can prescribe commercially available branded products — Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus — through licensed providers following appropriate clinical protocols. The restriction is specifically on compounded versions being produced and dispensed outside the narrow remaining legal pathways. Work with your pharmacy and legal counsel on your specific program structure.

Q: What happens if my pharmacy says they are still compounding GLP-1s legally?

A: Ask them to produce the written legal basis — specifically, which patient-specific or documented clinical-need exception applies, and whether their state board has issued any guidance. If they cannot produce that documentation quickly and clearly, treat it as a red flag. The pharmacy's legal risk and your clinic's legal risk are not the same, and you should not assume your pharmacy's confidence is a complete analysis.

Q: Is there a safe category for compounded medications?

A: Yes. Many compounded medications have a durable legal basis. Low-dose naltrexone, specific hormone formulations without commercially available equivalents, certain dermatological compounds, and medications on the active shortage list can all have legitimate compounding pathways. The key is the actual shortage status and the documented patient-specific need, not the general popularity of the molecule.

Q: Do I need to redo my LegitScript certification if my formulary changes?

A: You should notify LegitScript of material changes to your clinic's offerings and follow their update process. Operating outside your certified parameters is worse than not having certification at all. When in doubt, contact LegitScript directly — they have a merchant support process for exactly this situation.

Q: Should I shut down my GLP-1 program or pivot it?

A: That depends on your specific legal posture, pharmacy relationships, and patient pipeline. If your current program relies on broad compounded GLP-1 access, you cannot continue that program as structured. A pivot to branded products with prior auth support, combined with category expansion into TRT, HRT, or LDN, is the path most durable operators are taking. Consult your pharmacy law counsel before making public statements about any change in your program.

---

The GLP-1 compounding cliff was not a surprise to anyone paying close attention. The FDA's shortage framework was never designed to sustain a parallel GLP-1 market indefinitely, and once supply normalized, the legal basis for volume compounding was always going to erode.

What it exposed is which operators built on infrastructure and which ones built on arbitrage. The operators still standing — and growing — are the ones who owned their patient relationships, diversified their formulary, and built fulfillment that does not depend on any single regulatory determination remaining stable.

---

neolife connects Shopify-native telehealth stores to pharmacy fulfillment across TRT, HRT, hair, ED, skin, LDN, peptides, and more. Orders route in under 60 seconds, a licensed provider approves every script, and your clinic stays the system of record. The regulatory environment will keep moving. Your infrastructure should not be the fragile part.

[Talk to the neolife team about building a multi-category, pharmacy-agnostic fulfillment layer for your clinic.]

---

This post is for educational and operational awareness purposes only. It is not legal advice, medical advice, or pharmacy law counsel. Operators should verify all regulatory positions with qualified pharmacy law attorneys and their compounding pharmacy partners. Drug shortage status, compounding authority, and FDA enforcement guidance can change; check current FDA shortage lists and guidance documents directly.